Efficacy and Safety of Mycophenolate Mofetil in subjectswithSjogren's Syndrome

Sjogren's Syndrome Clinical Trial

Official title:

Efficacy and Safety of Mycophenolate Mofetil in subjectswithSjogren's Syndrome

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

• NCT number: NCT02691949
• Other study ID #: S10418-4
• Status: Enrolling by invitation
• Phase: Phase 2
• First received: February 16, 2016
• Last updated: September 21, 2016
• Start date: February 2016
• Est. completion date: April 2018

Study information

• Verified date: September 2016
• Source: Kaohsiung Medical University
• Contact: n/a
• Is FDA regulated: No
• Health authority: Taiwan: Ministry of Health and Welfare
• Study type: Interventional

Clinical Trial Summary

Past literature showed encouraging effects of mycophenolate on dryness symptoms and quality of life in patients with Sjogren's syndrome. Mycophenolate also has excellent immunomodulation effects in lupus nephritis. Currently Mycophenolate is only used in lupus nephritis and organ transplant. It is unknown whether low dosage of mycophenolate mofetil could be used to improve ocular dryness and oral dryness in patients with Sjogren's syndrome.

Description:

Sjogren's syndrome is one of the most common autoimmune diseases in Taiwan. It is characterized by keratoconjunctivitis sicca and xerostomia. Although it is well established that Sjogren's syndrome is caused by infiltration and destruction of lacrimal gland and salivary gland by lymphocytic cells, effective treatment of patients' symptoms is lacking. Hydroxychloroquine is the most well-studied medication in Sjogren's syndrome. However, recent clinical trials showed disappointing effects of hydroxychloroquine in Sjogren's syndrome. Thus there is an unmet need to find effective treatment for patient's bothering symptoms.

Mycophenolate is a selective inhibitor of inosinemonophosphate dehydrogenase which leads to inhibition of the de novo pathway of nucleotide synthesis. The antiproliferative effect of mycophenolate mainly affects activated T and B lymphocytes because the proliferation of these cells is critically dependent on the de novo purine synthesis compared with other eukaryotic cells. Since these lymphocytes have been suggested to play a pivotal role in the inflammation and immunopathogenesis of Sjogren's syndrome, mycophenolate might be a promising agent in the treatment of Sjogren's syndrome.

Past literature showed encouraging effects of mycophenolate on dryness symptoms and quality of life in patients with Sjogren's syndrome. Mycophenolate also has excellent immunomodulation effects in lupus nephritis. Currently mycophenolate is only used in lupus nephritis and organ transplant. It is unknown whether low dosage of mycophenolate could be used to improve ocular dryness and oral dryness in patients with Sjogren's syndrome.

Recruitment information / eligibility

• Status: Enrolling by invitation
• Enrollment: 54
• Est. completion date: April 2018
• Est. primary completion date: April 2018
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 20 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Diagnosis of primary Sjogren's syndrome based on the 2002 American-European Consensus criteria

2. Aged 20 to 75 years

3. Stable doses of oral corticosteroids(?5mg/d) for at least 4 weeks before enrollment

4. Intolerance or inadequate response to hydroxychloroquine and (pilocarpine or cevimeline), defined as less than 50mm on at least 2 of VAS including:

1. global assessment : 0mm (very bad) to 100mm (very good)

2. pain: 0mm (very bad) to 100mm (very good)

3. fatigue: 0mm (very bad) to 100mm (very good)

4. xerostomia: 0mm (very bad) to 100mm (very good)

5. Adequate contraception for patients of childbearing potential

Exclusion Criteria:

1. Receiving biologics during the 6 previous months or any other immunosuppressant (methotrexate, cyclophosphamide, cyclosporine, azathioprine, mycophenolate mofetil (MMF), mycophenolate sodium, leflunomide, penicillamine) during the previous month

2. Any one of laboratory abnormalities:

1. Serum creatinine =2 mg/dl

2. aspartate aminotransferase (AST) or alanine transaminase (ALT) more than 1.5 x upper normal range of the laboratory

3. Leukopenia (WBC<4000/µl)

4. Hb = 9 g/dl (5.6 mmol/l) for males and 8.5 g/dl (5.3 mmol/l) for females

5. Neutrophil less than 1.5 x 109/l

6. Platelet count less than 150 x 109/l

3. History of other autoimmune diseases

4. Use topical cyclosporine eyedrops, antihistamine, anticholinergic, antidepressant, or antipsychotic drug with possible effects on ocular dryness or oral dryness within 1 month

5. Pregnant or lactating women

6. Previous or current malignancies adequately controlled less than 5 years, hepatitis B, hepatitis C, HIV infection, tuberculosis, or diabetes

7. Subjects with serious infections requiring hospitalization within the last 12 months

8. Subjects with herpes zoster or cytomegalovirus that resolved less than 2 months before enrollment

9. Subjects who have received any live vaccines within 3 months

10. Underlying cardiac, pulmonary, metabolic, renal, hepatic, gastrointestinal, haematological or neurological conditions, chronic or latent infectious diseases or immune deficiency which places the patient at an unacceptable risk for participation in the study

11. History of recurring or chronic infections or underlying conditions which may further predispose patients to serious infection

12. Subjects who are impaired, incapacitated, or incapable of completing study-related assessments

13. History of allergy to mycophenolate sodium

14. Nausea, vomiting, diarrhea within 1 week before enrollment

15. History of psychosis, seizure, retinopathy

16. Infection 2 weeks before enrollment

17. Heart rate < 60/min at rest

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Sjogren's Syndrome
• Syndrome

Intervention

Drug:
• Mycophenolate mofetil
mycophenolate mofetil 1# BID-2# BID

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Kaohsiung Medical University

References & Publications (1)

Willeke P, Schlüter B, Becker H, Schotte H, Domschke W, Gaubitz M. Mycophenolate sodium treatment in patients with primary Sjögren syndrome: a pilot trial. Arthritis Res Ther. 2007;9(6):R115. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change of Composite Index of Sjogren's syndrome		baseline, 28 week	No
Secondary	ocular dryness	We will calculate the change of ocular dryness from baseline to week 28 (0mm [very bad] to 100mm [very good])	baseline, 28 week	No
Secondary	physician visual analog scale (VAS)	We will calculate the change of physician VAS from baseline to week 28 (0mm [very bad] to 100mm [very good])	baseline, 28 week	No
Secondary	Schirmer's test	We will calculate the change of Schirmer's test results from baseline to week 28	baseline, 28 week	No
Secondary	Saxon's test	We will calculate the change of Saxon's test results from baseline to week 28	baseline, 28 week	No
Secondary	heart rate	resting heart rate	baseline, 28 week	Yes
Secondary	blood pressure	resting blood pressure	baseline, 28 week	Yes
Secondary	leukocyte count	WBC count	baseline, 28 week	Yes
Secondary	Hb level	Hb level	baseline, 28 week	Yes
Secondary	platelet count	platelet count	baseline, 28 week	Yes